Type 1 diabetes (T1D) results from immune destruction of pancreatic beta cells. Published data show that , dextran sulfate (DXS), a compound already used in clinic as an anticoagulant, can inhibit the activation of human immune cells in culture that are cytotoxic for the pancreatic beta cell. Preliminary data suggest that DXS can also prevent the progression of diabetes in a mouse model of T1D. Furthermore, DXS can also protect rodent and human pancreatic beta cells from cytokines. We have also found that DXS might be a potent regenerative agent for the beta cell. Taken together, these studies suggest that DXS might potentially prevent T1D development and protect beta cells from cell death induced by inflammatory agents. Based on these important observations we want to: SA1. To analyze the effect of DXS in mouse and human beta cell survival and proliferation in vitro and the mechanisms involved in these effects. SA2. To determine the effect of DXS in mouse and human beta cell proliferation and regeneration in vivo and the mechanisms involved in these effects. SA3. To unravel the potential therapeutic effects of DXS in pre-diabetic and diabetic NOD mice. We believe these studies will provide the required information to determine the effectiveness of DXS as a therapeutic agent for the treatment of T1D.
|Effective start/end date||1/01/14 → 31/12/16|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.